SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Decline in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 19,800 shares, a drop of 34.0% from the January 15th total of 30,000 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 53,500 shares, the short-interest ratio is presently 0.4 days.

SOPHiA GENETICS Price Performance

SOPH stock opened at $3.82 on Friday. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average price of $3.41 and a 200 day moving average price of $3.56. SOPHiA GENETICS has a 12 month low of $2.70 and a 12 month high of $7.37. The stock has a market cap of $249.69 million, a PE ratio of -3.60 and a beta of 1.03.

Institutional Trading of SOPHiA GENETICS

Large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. grew its position in SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after purchasing an additional 86,764 shares during the period. Federated Hermes Inc. increased its holdings in SOPHiA GENETICS by 40.5% in the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock worth $312,000 after acquiring an additional 28,819 shares in the last quarter. Green Alpha Advisors LLC raised its holdings in shares of SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after acquiring an additional 25,686 shares during the last quarter. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at approximately $70,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of SOPHiA GENETICS by 23.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $68,000 after acquiring an additional 4,115 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Craig Hallum assumed coverage on SOPHiA GENETICS in a research note on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.